SCHEMBL5163590

SCHEMBL5163590

CC(C)OC(=O)CC(=O)c1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.50
KDM4E B2RXH2 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
PKM P14618 2/20 0.50
MITF O75030 1/20 0.50
ALDH1A1 P00352 4/20 0.48
HTT P42858 1/20 0.48
CTNNB1 P35222 3/20 0.47
WNT3A P56704 2/20 0.47
GRM4 Q14833 2/20 0.47
TSHR P16473 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
P4HTM Q9NXG6 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALPL P05186 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL852344 0.83 SMN1; SMN2 (0.57) SMN1; SMN2KDM4ENPC1RAB9APKM
SCHEMBL5162472 0.80 TSHR (0.43) SMN1; SMN2KDM4ENPC1RAB9APKM
SCHEMBL5161597 0.80 P2RX7 (0.49) CTNNB1WNT3AGRM4TSHRMAPT
SCHEMBL601821 0.79 LMNA (0.54) SMN1; SMN2KDM4ENPC1RAB9APKM
SCHEMBL29355245 0.79 CES2 (0.64) SMN1; SMN2ALDH1A1CTNNB1WNT3AGRM4
SCHEMBL253276 0.79 CES2 (0.64) SMN1; SMN2ALDH1A1CTNNB1WNT3AGRM4
SCHEMBL9944382 0.78 KMT2A (0.58) SMN1; SMN2KDM4ENPC1RAB9APKM
SCHEMBL30731163 0.78 KMT2A (0.58) SMN1; SMN2KDM4ENPC1RAB9APKM
SCHEMBL5158131 0.78 SMN1; SMN2 (0.48) SMN1; SMN2KDM4ENPC1RAB9APKM
SCHEMBL28018365 0.78 SMN1; SMN2 (0.44) SMN1; SMN2KDM4ENPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO SMN1; SMN2 4683/4885KDM4E 862/4885NPC1 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.